Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections

Launched by THE SECOND HOSPITAL OF NANJING MEDICAL UNIVERSITY · Mar 27, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called fecal microbiota transplantation (FMT) for patients who have severe intestinal infections that haven’t improved with standard treatments. Specifically, it focuses on patients with infections like Clostridioides difficile, which can cause severe diarrhea and other complications. The trial is part of a national effort in China to gather information about how safe and effective this treatment is for people who continue to have these infections despite trying other options.

To participate in the trial, patients must have been diagnosed with a refractory intestinal infection and are seeking rescue FMT through the China Microbiota Transplantation System between September 2015 and December 2029. One important thing to note is that participants need to be followed up for at least 12 weeks after receiving the treatment to ensure their progress is monitored. If you or someone you know is considering this treatment, it could be an opportunity to help improve the understanding of FMT's benefits and risks for patients facing these challenging infections.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria: National patients with refractory intestinal infections receiving rescue FMT from the China Microbiota Transplantation System from September 2015 to December, 2029 will be included.
• • -
• • Exclusion Criteria: Patients will be excluded from the analysis if they are not followed up for at least 12 weeks post-FMT.
• • -